GSK-3 beta Antibody (3D10) - BSA Free

Flow Cytometry: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470]

Flow Cytometry: GSK-3 beta Antibody (3D10) [NBP1-47470] - An intracellular stain was performed on HeLa cells with GSK-3 beta (3D10) antibody NBP1-47470PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.

Western Blot: GSK-3 beta Antibody (3D10)BSA Free [NBP1-47470]

Western Blot: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis using GSK3 beta mouse mAb against A549 (1), K562 (2), PC-12 (3), NIH/3T3 (4), and HEK293 (5) cell lysates.

Immunohistochemistry-Paraffin: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470]

Immunohistochemistry-Paraffin: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of paraffin-embedded human lung cancer (left) and breast cancer tissues (right) using GSK3 beta mouse mAb with DAB staining.

Flow Cytometry: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470]

Flow Cytometry: GSK-3 beta Antibody (3D10) [NBP1-47470] - Flow cytometric analysis of Hela cells using GSK3 beta mouse mAb (green) and negative control (purple).

Simple Western: GSK-3 beta Antibody (3D10)BSA Free [NBP1-47470]

Simple Western: GSK-3 beta Antibody (3D10) [NBP1-47470] - Simple Western lane view shows a specific band for GSK-3 Beta in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Simple Western: GSK-3 beta Antibody (3D10)BSA Free [NBP1-47470]

Simple Western: GSK-3 beta Antibody (3D10) [NBP1-47470] - Simple western analysis of mouse brain tissue (striatum) from 4 month old Tg4150 and wildtype mice. Image courtesy of Dr. Brandi Wasek-Patterson at Baylor Research Institute, Institute of Metabolic Disease.

Immunocytochemistry/ Immunofluorescence: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470] -

Immunocytochemistry/ Immunofluorescence: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470] - Fap1-inhibition with SLV peptide increases Fas & Gsk3 beta phosphorylation in CD133+ cells in a murine xenograft modelSW620 cells were injected in the flanks of athymic Nude mice & tumor volume was determination biweekly. Mice were treated weekly with oxaliplatin (days 0, 7 & 14) & injected daily with Fap1 blocking SLV peptide or VLS control peptide, or treated with SLV or VLS peptide alone (n=12 per cohort). Tumors were simultaneously harvested from cohorts of mice when control tumors were >2,000 mm3. (A) SLV peptide increases Fas phosphorylation in CD133+ xenograft tumors with or without oxaliplatin. Immunofluorescent detection of phospho-Fas or CD133 was performed with DAPI staining of nuclei. (B) SLV peptide increases Gsk3 beta phosphorylation in CD133+ xenograft tumors with or without oxaliplatin. Immunofluorescent detection of phospho-Gsk3 beta or CD133 was performed with DAPI staining of nuclei. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29899829), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470] -

Immunocytochemistry/ Immunofluorescence: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470] - Fap1-inhibition with SLV peptide increases phosphorylation of Fap1-substrates Fas & Gsk3 beta in a murine xenograft modelSW620 cells were injected in the flanks of athymic Nude mice & tumor volume was determination biweekly. Mice were treated weekly with oxaliplatin (days 0, 7 & 14) & injected daily with Fap1 blocking SLV peptide or VLS control peptide, or treated with SLV or VLS peptide alone (n=12 per cohort). Tumors were simultaneously harvested from cohorts of mice when control tumors were >2,000 mm3. (A) SLV peptide increases gland formation in xenograft tumors with or without oxaliplatin. Histology was analyzed by hematoxylin/ eosin staining. Fap1 expression was determined by immunofluorescence. Relative fluorescent intensity (RFI) of Fap1 staining is indicated below relevant panels. (B) SLV peptide increases Fas-phosphorylation in xenograft tumors with or without by oxaliplatin. Immunofluorescent detection of total versus phospho-Fas was performed with DAPI staining of nuclei. Areas without gland formation were selected for this study. (C) SLV peptide increases Gsk3 beta-phosphorylation with or without oxaliplatin. Immunofluorescent detection of total versus phospho- Gsk3 beta was performed with DAPI staining of nuclei. Areas without gland formation were selected for this study. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29899829), licensed under a CC-BY license. Not internally tested by Novus Biologicals.